Literature DB >> 11329458

Intra- and interlaboratory variabilities of results obtained with the Quantiplex human immunodeficiency virus type 1 RNA bDNA assay, version 3.0.

J A Kellogg1, P V Atria, J C Sanders, M E Eyster.   

Abstract

Normal assay variation associated with bDNA tests for human immunodeficiency virus type 1 (HIV-1) RNA performed at two laboratories with different levels of test experience was investigated. Two 5-ml aliquots of blood in EDTA tubes were collected from each patient for whom the HIV-1 bDNA test was ordered. Blood was stored for no more than 4 h at room temperature prior to plasma separation. Plasma was stored at -70 degrees C until transported to the Central Pennsylvania Alliance Laboratory (CPAL; York, Pa.) and to the Hershey Medical Center (Hershey, Pa.) on dry ice. Samples were stored at < or =-70 degrees C at both laboratories prior to testing. Pools of negative (donor), low-HIV-1-RNA-positive, and high-HIV-1-RNA-positive plasma samples were also repeatedly tested at CPAL to determine both intra- and interrun variation. From 11 August 1999 until 14 September 2000, 448 patient specimens were analyzed in parallel at CPAL and Hershey. From 206 samples with results of > or =1,000 copies/ml at CPAL, 148 (72%) of the results varied by < or =0.20 log(10) when tested at Hershey and none varied by >0.50 log(10). However, of 242 specimens with results of <1,000 copies/ml at CPAL, 11 (5%) of the results varied by >0.50 log(10) when tested at Hershey. Of 38 aliquots of HIV-1 RNA pool negative samples included in 13 CPAL bDNA runs, 37 (97%) gave results of <50 copies/ml and 1 (3%) gave a result of 114 copies/ml. Low-positive HIV-1 RNA pool intrarun variation ranged from 0.06 to 0.26 log(10) while the maximum interrun variation was 0.52 log(10). High-positive HIV-1 RNA pool intrarun variation ranged from 0.04 to 0.32 log(10), while the maximum interrun variation was 0.55 log(10). In our patient population, a change in bDNA HIV-1 RNA results of < or =0.50 log(10) over time most likely represents normal laboratory test variation. However, a change of >0.50 log(10), especially if the results are >1,000 copies/ml, is likely to be significant.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11329458      PMCID: PMC96101          DOI: 10.1128/CDLI.8.3.560-563.2001

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  15 in total

1.  Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories.

Authors:  B Yen-Lieberman; D Brambilla; B Jackson; J Bremer; R Coombs; M Cronin; S Herman; D Katzenstein; S Leung; H J Lin; P Palumbo; S Rasheed; J Todd; M Vahey; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

2.  Comparison of the Quantiplex version 3.0 assay and a sensitized Amplicor monitor assay for measurement of human immunodeficiency virus type 1 RNA levels in plasma samples.

Authors:  H C Highbarger; W G Alvord; M K Jiang; A S Shah; J A Metcalf; H C Lane; R L Dewar
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

3.  Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR.

Authors:  D H Schwartz; O B Laeyendecker; S Arango-Jaramillo; R C Castillo; M J Reynolds
Journal:  Lancet       Date:  1997-07-26       Impact factor: 79.321

4.  Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  D G Murphy; L Côté; M Fauvel; P René; J Vincelette
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

5.  Clinical comparison of an enhanced-sensitivity branched-DNA assay and reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma.

Authors:  F S Nolte; J Boysza; C Thurmond; W S Clark; J L Lennox
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

6.  Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5.

Authors:  T Elbeik; E Charlebois; P Nassos; J Kahn; F M Hecht; D Yajko; V Ng; K Hadley
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

7.  Biological and virologic characteristics of primary HIV infection.

Authors:  T W Schacker; J P Hughes; T Shea; R W Coombs; L Corey
Journal:  Ann Intern Med       Date:  1998-04-15       Impact factor: 25.391

8.  Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  R Schuurman; D Descamps; G J Weverling; S Kaye; J Tijnagel; I Williams; R van Leeuwen; R Tedder; C A Boucher; F Brun-Vezinet; C Loveday
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

9.  Cell-free plasma human immunodeficiency virus type 1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction.

Authors:  R W Coombs; D R Henrard; W F Mehaffey; J Gibson; E Eggert; T C Quinn; J Phillips
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

10.  Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes.

Authors:  M Holodniy; L Mole; B Yen-Lieberman; D Margolis; C Starkey; R Carroll; T Spahlinger; J Todd; J B Jackson
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

View more
  1 in total

1.  Precision across the analytical measuring range of a quantitative real-time PCR assay for cytomegalovirus detection among three clinical laboratories.

Authors:  Thomas E Grys; Doreen L Duquette; Bruce White; Cole Irish; D Jane Hata; Bobbi S Pritt
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.